Group 1 - The company Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced the resignation of Mr. Zhang Hui from his positions as Co-Company Secretary, Deputy General Manager, Chief Financial Officer, and Board Secretary due to personal career planning reasons, effective from February 8, 2026 [2][14][24] - Ms. Xiao Jieyu has been appointed as the new Chief Financial Officer and Board Secretary, effective from February 8, 2026, with an annual base salary of RMB 750,000 and discretionary bonuses based on her performance and the overall performance of the group [2][12][24] Group 2 - Ms. Xiao Jieyu, aged 43, holds a Bachelor's degree in Plant Protection from Huazhong Agricultural University and a Master's degree in Pharmacology from Shanghai Pharmaceutical Industry Research Institute [3][15] - Prior to joining the company, Ms. Xiao held various positions in investment and financing roles, including Senior Investment Manager at Wuhan Optics Valley Venture Capital and Deputy General Manager at Wuhan East Lake High-tech Equity Investment Management Co., Ltd. [4][16] Group 3 - Mr. Zhang Hui, aged 56, joined the company in August 2024 and was responsible for overseeing the financial operations, corporate governance, investor relations management, and company secretarial matters [5][17] - Mr. Zhang has over 16 years of experience in investment banking and financing, having worked at various institutions including DBS Bank, BNP Paribas, and Deutsche Bank [6][18]
上市仅仨月！这家公司更换CFO！